预约演示
更新于：2025-04-17
Mirabegron
米拉贝隆
更新于：2025-04-17
概要
基本信息
药物类型 小分子化药 |
别名 Betmiga PR、Mirabegron (USAN/JAN)、Myrbetriq Granules + [8] |
作用方式 拮抗剂 |
作用机制 GP IIb/IIIa拮抗剂(糖蛋白 IIb/IIIa拮抗剂) |
治疗领域 |
最高研发阶段批准上市 |
首次获批日期 日本 (2011-07-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H24N4O2S |
InChIKeyPBAPPPCECJKMCM-IBGZPJMESA-N |
CAS号223673-61-8 |
关联
244
项与 米拉贝隆 相关的临床试验NCT05713799
Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity
NCT06803030
A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial
NCT06791460
Pegylated Liposomal Doxorubicin Plus Adebrelimab with or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial
100 项与 米拉贝隆 相关的临床结果
登录后查看更多信息
100 项与 米拉贝隆 相关的转化医学
登录后查看更多信息
100 项与 米拉贝隆 相关的专利（医药）
登录后查看更多信息
1,535
项与 米拉贝隆 相关的文献（医药）2025-05-01BIOMEDICAL CHROMATOGRAPHY
Optimizing Mirabegron Stability in Human Plasma: Method Development, Validation Through Integration of Esterase Inhibitors and Stabilizers
Article
作者: Shah, Ujashkumar ; Tawari, Santosh
ABSTRACT:
The stability of mirabegron in human plasma is addressed in this study. The susceptibility of Mirabegron to enzymatic and oxidative degradation requires the integration of esterase inhibitors and stabilizers into the analytical process. Esterase inhibitors, including sodium fluoride and dichlorvos, as well as stabilizing agents such as malic acid, ascorbic acid, acetic acid, citric acid and sodium bicarbonate were also investigated to mitigate this issue. Samples were prepared through solid‐phase extraction (SPE) utilizing Strata‐X cartridges. The optimization of chromatographic separation was conducted using a C18 Kromasil column with a solvent mixture consisting of ammonium formate and acetonitrile. Detection employed electrospray ionization (ESI) in positive ionization mode, focusing on MRM transitions of 397.2 → 260.1 for mirabegron and 402.2 → 260.1 for mirabegron D5. The method exhibited an accuracy range of 95.67% to 102.85% and precision of 0.52% to 2.31% for a linearity ranged from 0.100 to 102.496 ng/mL. An advantage of this method is its stability, requiring only a minimal plasma volume of 100 μL, a quick runtime of 3 min, and a high recovery rate of 92.93%, making it highly efficient and reliable for bioequivalence testing, therapeutic monitoring and pharmacokinetic studies.
2025-05-01Urologia Journal
Short-term effect of mirabegron on female sexual function in women with overactive bladder
Article
作者: Karabacak, Nihat ; Onaran, Metin ; Koparal, Murat Yavuz ; Erten, Kadir Şerefhan ; Çetin, Serhat ; Şen, İlker
Background::
Overactive bladder (OAB) is a common syndrome that can negatively affect patients’ daily activities, sleep patterns, mental health, sexual function, and general health. In addition to reducing the frequency of attacks, treatment of OAB can be expected to improve the psychological and sexual health of patients.
Aims::
To evaluate the effects of mirabegron used in the treatment of overactive bladder (OAB) on female sexual function (FSF).
Methods::
This retrospective study includes 48 sexually active women who were diagnosed with overactive bladder and treated with a daily oral dose of 50 mg mirabegron between November 2021 and March 2022. The evaluation of FSF was conducted using female sexual function index (FSFI) along with urinary parameters before the start of the treatment and at the 6th week of the treatment.
Results::
In the study, out of 48 participants, 40 (83.3%) were identified with the dry type and 8 (16.7%) with the wet type OAB. The median age when diagnosed was 43.5 years. Although the decrease in the Overactive Bladder Questionnaire (OAB-V8) score did not reach statistical significance in the entire patient group after treatment (
p
= 0.058), a statistically significant decrease in the International Consultation on Incontinence Questionnaire–Short Form (ICIQ-SF) score was detected in the wet type OAB group (
p
< 0.001). During the assessment of sexual function, there was a statistically significant increase in the FSFI score, from 21.4 to 23.05, by the 6th week of treatment (
p
= 0.017). Specifically, the scores for desire, lubrication, and satisfaction showed a statistically significant post-treatment improvement (
p
< 0.001,
p
= 0.049, and
p
= 0.035, respectively).
Conclusion::
The study indicates that a 6-week regimen of a daily 50 mg mirabegron dose enhanced sexual function in women. This beneficial impact of mirabegron on sexual health should be taken into account when selecting a treatment for OAB.
2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Uncoupling protein 1-mediated protective effects of β3-adrenergic receptor agonist on kidney fibrosis via promoting adipose tissue browning in diabetic mice
Article
作者: Zhang, Yun ; Sui, Wenhai ; Wang, Xinlu ; Zhao, Kunsheng ; Meng, Linlin
BACKGROUND:
Diabetes mellitus (DM) is a global health concern. Diabetic kidney disease (DKD) is a prevalent severe complication of DM and therapy is urgently needed. Adipose tissue (AT) plays a crucial role in the energy mediation through glucolipid metabolism. Mirabegron is a specific β3-adrenergic receptor agonist, which can activate thermogenesis in adipocytes, improve energy consumption, and increase insulin sensitivity and glucose tolerance. Therefore, mirabegron may play a role in DKD pathogenesis. However, its effects and precise mechanisms remain unclear.
METHODS:
A DKD mouse model based on type 2 DM (T2DM) was constructed and treated with mirabegron. Mice with AT surgically removed and mice with uncoupling protein 1 (Ucp1) knockout were used to confirm whether thermogenesis induced by mirabegron was the key process.
RESULTS:
Mirabegron promoted AT browning in DKD mice. Mirabegron increased insulin sensitivity, promoted glucolipid metabolism, reduced inflammatory factor levels in kidney tissue, and improved renal function and fibrosis in DKD mice. Notably, all of these benefits disappeared in AT-removed DKD mice or in Ucp1 knockout DKD mice.
CONCLUSIONS:
Mirabegron protects against kidney fibrosis in DM mice by activating AT thermogenesis via the UCP1 pathway. Thus, mirabegron may provide a promising potential option for DKD therapy.
100 项与 米拉贝隆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 神经源性逼尿肌过度活动 | 欧盟 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 冰岛 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 列支敦士登 | 2024-09-05 | |
| 神经源性逼尿肌过度活动 | 挪威 | 2024-09-05 | |
| 膀胱过度活动症综合征 | 欧盟 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 冰岛 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 列支敦士登 | 2012-12-20 | |
| 膀胱过度活动症综合征 | 挪威 | 2012-12-20 | |
| 膀胱过度活动症 | 日本 | 2011-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 间质性膀胱炎 | 临床3期 | 美国 | 2016-08-01 | |
| 尿失禁 | 临床3期 | 美国 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 亚美尼亚 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 澳大利亚 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 奥地利 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 比利时 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 加拿大 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 捷克 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 丹麦 | 2013-07-10 | |
| 尿失禁 | 临床3期 | 芬兰 | 2013-07-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 20 | Mirabegron 100 mg/day + Placebo | 繭膚積鬱憲餘積衊膚壓(獵鬱選襯構顧網夢膚簾) = 餘構衊積餘壓簾壓積憲 壓鬱網艱鹹壓遞積襯築 (鹽壓觸齋範觸願構築鑰 ) 更多 | 积极 | 2024-09-27 | |
Mirabegron 200 mg/day + Placebo | 繭膚積鬱憲餘積衊膚壓(獵鬱選襯構顧網夢膚簾) = 艱壓餘壓範網構襯繭齋 壓鬱網艱鹹壓遞積襯築 (鹽壓觸齋範觸願構築鑰 ) 更多 | ||||||
临床1/2期 | - | 30 | Placebo (Placebo) | 鹹鑰憲壓衊遞膚網觸鑰(觸壓糧淵鏇獵顧網顧網) = 壓鏇鏇襯憲窪膚夢願夢 膚壓蓋廠選鏇廠鑰窪襯 (觸憲壓構鏇襯醖鹹選膚, 67.8) 更多 | - | 2024-07-12 | |
(100 mg Mirabegron) | 鹹鑰憲壓衊遞膚網觸鑰(觸壓糧淵鏇獵顧網顧網) = 築鏇鬱餘選鹽醖範夢願 膚壓蓋廠選鏇廠鑰窪襯 (觸憲壓構鏇襯醖鹹選膚, 75.7) 更多 | ||||||
N/A | - | - | 壓網簾構餘選積鏇廠範(顧夢夢觸積積繭鏇窪製) = 衊夢觸壓襯壓蓋蓋壓獵 齋廠願構衊憲鑰淵鏇獵 (築鬱構構遞齋網夢糧廠 ) | 积极 | 2024-05-01 | ||
Anticholinergics | 壓網簾構餘選積鏇廠範(顧夢夢觸積積繭鏇窪製) = 繭壓憲淵鹹壓選窪糧選 齋廠願構衊憲鑰淵鏇獵 (築鬱構構遞齋網夢糧廠 ) | ||||||
临床2期 | 57 | 襯醖蓋鹹鹹鏇構衊憲憲(壓選窪構顧淵廠遞觸顧) = Baseline and follow-up data: placebo: 13 ± 7 to 13 ± 5; mirabegron: 12 ± 6 to 13 ± 8 鏇築膚積構淵網範膚艱 (襯夢艱淵網廠淵鬱淵繭 ) 更多 | 积极 | 2024-03-05 | |||
Placebo | |||||||
临床3期 | 26 | (Mirabegron (5 to < 12 Years)) | 繭鑰壓願憲繭鹹壓鏇衊(壓構鏇夢窪艱淵糧繭廠) = 選膚衊顧築鏇醖鹽夢艱 願鑰餘積獵鹽衊顧膚鹹 (鹽積鑰壓鏇鑰願築膚夢, 0.89) 更多 | - | 2023-12-28 | ||
Placebo (Placebo (5 to < 12 Years)) | 繭鑰壓願憲繭鹹壓鏇衊(壓構鏇夢窪艱淵糧繭廠) = 積顧憲鹹鏇衊鹹築齋鏇 願鑰餘積獵鹽衊顧膚鹹 (鹽積鑰壓鏇鑰願築膚夢, 0.89) 更多 | ||||||
临床2期 | 296 | Mirabegron 50 mg/d | 願簾獵襯膚範鏇壓積憲(範憲鬱顧網齋選鹹艱願) = 選鏇餘蓋餘顧製範糧鏇 願鹹鹹網餘醖糧鑰糧憲 (顧鏇簾築選觸齋網願製, -0.15 ~ 2.74) | 不佳 | 2023-11-01 | ||
临床4期 | 28 | (Mirabegron) | 夢蓋鬱構繭觸蓋築鹽餘(壓選醖鬱鏇廠鬱鬱鬱廠) = 齋範淵選廠製簾獵憲鏇 鹹鑰膚艱齋築夢憲糧艱 (膚衊夢廠範衊衊廠淵夢, 0.48) 更多 | - | 2023-10-18 | ||
Placebo (Placebo) | 夢蓋鬱構繭觸蓋築鹽餘(壓選醖鬱鏇廠鬱鬱鬱廠) = 夢網網願齋積糧鹽遞憲 鹹鑰膚艱齋築夢憲糧艱 (膚衊夢廠範衊衊廠淵夢, 0.84) 更多 | ||||||
临床4期 | 54 | Posterior Tibial Nerve Stimulation (PTNS)+Mirabegron 50 MG (Posterior Tibial Nerve Stimulation With Mirabegron) | 積鹹壓膚鑰鏇製鏇壓蓋(範襯蓋衊顧襯範膚製鑰) = 艱夢憲願鬱餘願選繭廠 窪獵憲壓網觸鬱觸膚繭 (繭糧壓繭觸鹹繭鑰鏇糧, 3.9) 更多 | - | 2023-07-20 | ||
Posterior Tibial Nerve Stimulation (PTNS) (Posterior Tibial Nerve Stimulation Plus Placebo) | 積鹹壓膚鑰鏇製鏇壓蓋(範襯蓋衊顧襯範膚製鑰) = 願襯積襯糧積窪艱憲鬱 窪獵憲壓網觸鬱觸膚繭 (繭糧壓繭觸鹹繭鑰鏇糧, 5.4) 更多 | ||||||
临床2期 | 11 | (Treatment Arm) | 選襯構繭蓋糧獵積願廠(齋繭繭願築蓋範築膚願) = 糧繭範獵鬱壓獵遞築壓 遞積構願網醖鬱淵蓋膚 (構鏇繭糧蓋鹹獵餘選製, 餘齋鑰夢觸餘鏇糧願壓 ~ 鏇齋窪糧築網繭衊夢糧) 更多 | - | 2023-06-13 | ||
Placebo (Placebo Arm) | 選襯構繭蓋糧獵積願廠(齋繭繭願築蓋範築膚願) = 製繭夢齋構壓糧艱淵醖 遞積構願網醖鬱淵蓋膚 (構鏇繭糧蓋鹹獵餘選製, 觸窪醖願窪簾鹽網觸膚 ~ 艱願憲鏇鑰蓋選壓積範) 更多 | ||||||
N/A | - | 餘鬱餘獵膚夢願築製積(觸網觸願鬱夢願醖壓齋) = 選膚壓蓋窪憲積鹽觸襯 獵鑰積壓鏇壓築繭觸範 (艱艱餘積窪衊鏇構遞醖 ) | - | 2023-04-01 | |||
Placebo | 餘鬱餘獵膚夢願築製積(觸網觸願鬱夢願醖壓齋) = 鑰網鹹醖膚壓蓋獵獵願 獵鑰積壓鏇壓築繭觸範 (艱艱餘積窪衊鏇構遞醖 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用